Quick Financials Update
On August 29, 2013, Avita Medical Ltd (OTCQX:AVMXY) reported financial results for the six months and full year ended June 30, 2013. Total revenues for the six months ended June 30, 2013 were $2.18 million, up 13% over the same period in 2012. Revenues were driven by $1.46 million in product sales, consisting of sales of the ReCell® Spray-On Skin product in Europe and sales of the Breath-A-Tech® spacer and Funhaler® children's inhaler in Australia, and $0.72 million in grants relating to the U.S. Department of Defense and other income. For the full year 2013, revenues totaled $4.05 million, consisting of $2.82 million in product sales from ReCell, Breath-A-Tech, and Funhaler, and $1.24 million in...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|